Lack of TNF-α Gene Polymorphism (rs1799724) Association with Sustained Virological Response in Iranian Patients with Chronic HCV Infection |
Larijani, Mona Sadat
(Department of Hepatitis and AIDS, Pasteur Institute of Iran)
Bahiraei, Narges (Islamic Azad University, Varamin Branch) Nikbin, Mehri (Iran Hepatitis Network, Pasteur Institute of Iran) Mohajel, Nasir (Department of Virology, Pasteur Institute of Iran) Rad, Leila Naghizadeh (Department of Hepatitis and AIDS, Pasteur Institute of Iran) Baghbani, Fahimeh (Islamic Azad University, Varamin Branch) Mapar, Maryam (Department of Hepatitis and AIDS, Pasteur Institute of Iran) Sadat, Seyed Mehdi (Department of Hepatitis and AIDS, Pasteur Institute of Iran) |
1 | Roba M. Talaat , Ahmed A. Esmail , Reda Elwakil , et al (2011). Tumor necrosis factora, -308 g/a polymorphism 1and risk of hepatocellularcarcinoma in hepatit c virus infect pateints department of tropical medicine. Chinese J Cancer, 31, 29-35. |
2 | Sy T, Jamal MM (2006). Epidemiology of Hepatitis C Virus (HCV) Infection. Int J Med, 3, 41-6. |
3 | Thio CL (2008). Host genetic factors and antiviralimmune responses to HCV. Clin Liver Dis, 12, 713-26. DOI |
4 | Zeisel MB, Lupberger J, Fofana I, et al (2013). TF.Host-targeting agents for prevention and treatment of chronic hepatitis C "Perspectives and challenges. J Hepatol, 58, 375-84. DOI |
5 | Gane EJ, Stedman CA, Hyland RH, et al (2013). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med, 368, 34-44. DOI |
6 | Gaurav Dogra, Anita Chakravarti, Premashish Kar, et al (2011). Polymorphism of tumor necrosisfactor-a and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-a therapy response. Human Immunol, 72, 935-9. DOI |
7 | Hoofnagle JH (2002). Course and outcome of hepatitis C. Hepatol, 36, 21-9. DOI |
8 | Guo X, Zhao Z, Xie J, et al (2012). Prediction of response to pegylated-interferon- and ribavirin therapy in Chinese patients infected with different Hepatitis C virus genotype. Virol J, 9, 123. DOI |
9 | Heba F. Pasha, Mohamed I. Radwan, Hoda A, et al (2013). Cytokines genes polymorphisms in chronic hepatitis C: Impact on susceptibility to infection and response to therapy. Cytokine, 61, 478-84. DOI |
10 | Henderson DK (2003). Managing occupational risksfor hepatitis c transmission in the health care setting. Clin Microbiol Rev, 16, 546-68. DOI |
11 | Kau A, Vermehren J, Sarrazin C (2008). Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol, 49, 634-51. DOI |
12 | Khodabandehloo M, Daem Roshani (2014). Prevalence of hepatitis c virus genotypes in iranian patients: a systematic review and meta-analysis. Hepat Mon, 14, 22915. |
13 | Chloe L (2008). Host genetic factors and antiviral immune responses to HCV. Clin Liver Dis, 12, 713-26. DOI |
14 | Aman W, Mousa S, Shiha G, et al (2012). Current status and future directions in the management of chronic hepatitis C. Virol J, 2, 9-57. |
15 | Andrea S, Antonia D, Clementi M (2012). New therapeutic options for HCV infection in the monoclonal antibody era. New Microbiologica, 35, 387-97. |
16 | Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al (2006). Tumor necrosis factor-a promoter polymorphism at position _308 predicts response to combination therapy in hepatitis c virus infection. J Infectious Diseases, 193, 98-101. DOI |
17 | Mohamed I. Radwan a, Heba F. Pasha b, Rasha H. Mohamed c, et al (2012). Influence of transforming growth factor-b1 and tumor necrosis factor-a genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine, 60, 271-6. DOI |
18 | Klevens RM, Hu DJ, Jiles R, et al (2012). Evolving epidemiology of hepatitis c virus in the united states. Clin Infect Dis, 55, 3-9. DOI |
19 | Manns MP, McHutchison JG, Gordon SC, et al (2001). Peginterferon alfa-2b plus ribavirin compared withinterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet, 358, 958-65. DOI |
20 | Mirjam B, Joachim A, Isabel A (2013). Host-targeting agents for prevention and treatment of chronic Hepatitis C " Perspectives and challenges, J Hepatol, 58, 375-84. DOI |
21 | Ray Kim W (2010). Global epidemiology and burden of hepatitis C. Microbes Infect, 4, 1219-25.1. |
22 | Mohd Hanafiah K, Groeger J, Flaxman AD, et al (2013). Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol, 57, 1333-42. DOI |